



ASX Release
3 July 2020

ASX Code: MEM

Cancellation of Options

Australian-based bio-separations company Memphasys Limited (ASX: MEM) ("Memphasys" or "the Company") wishes to advise that 2,199,292 Unlisted options to acquire fully paid ordinary shares exercisable at \$0.1142 on or before 22 October 2021, that were issued to non-executive directors on 22 October 2019, have been cancelled effective 30 June 2020.

This announcement has been approved for release by Alison Coutts, Executive Chair of Memphasys Limited.

ENDS

For further information please contact:

Alison Coutts
Executive Chairman
Memphasys Limited
T: +61 2 8415 7300
E: alison.coutts@memphasys.com

Andrew Metcalfe
Company Secretary
Memphasys Limited
T: +0412 125 090
E: andrew@accosec.com

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Website: www.memphasys.com